Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Agenus Inc (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Summary

Agenus Inc (Agenus) is a clinical-stage immuno-oncology company. It focuses on the development and commercialization of immunotherapeutics for the treatment of diseases in the fields of cancer and infectious diseases. Its business activities include product research and development, regulatory and clinical affairs, manufacturing, corporate finance and development, business development, marketing, intellectual property prosecution and administrative functions. The companys key technology portfolio includes Checkpoint Antibody Program, Saponin Platform and Heat Shock Protein (HSP) Platform. Its major products in the pipeline include candidates for the treatment of genital herpes, glioma, and multiple cancer types and infectious diseases such as malaria and shingles. The company has partnerships with several pharmaceutical companies such as GSK, Incyte, and universities such as UC San Francisco and UW Seattle. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

Agenus Inc (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

TABLE OF CONTENTS

2
List of Tables 4
List of Figures 5
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Agenus Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Agenus Acquires Antibody Manufacturing Facilities from XOMA 12
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 13
Agenus Acquires Antibody Assets of Celexion 14
Venture Financing 15
PhosImmune Raises Funds through Venture Financing 15
Partnerships 16
Agenus Enters into Agreement with National Cancer Institute 16
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 16
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 18
4-Antibody Enters Into Co-Development Agreement With Human Genome Sciences 18
4-Antibody Enters Into Co-Development Agreement With Ludwig Institute 19
Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center 20
Licensing Agreements 21
Agenus Enters into Licensing Agreement with IONTAS 21
Incyte to Enter into Licensing Agreement with Agenus 21
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 23
Agenus Enters into Licensing Agreement with Diatheva 24
Merck Extends Licensing Agreement with Agenus 25
PhosImmune Enters into Licensing Agreement with Pure MHC 26
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 26
Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon 27
Agenus Enters Into Licensing And Development Agreement With NewVac For Oncophage 28
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon 29
Equity Offering 30
Agenus Plans to Raise Funds through Public Offering of Shares 30
Agenus Raises USD80 Million in Public Offering of Shares 31
Celexion to Sell Shares of Agenus for USD4.3 Million 33
Agenus to Raise USD35 Million in Private Placement of Common Stock 34
Agenus Completes Public Offering Of Shares For US$60 Million 35
Agenus Completes Private Placement Of Shares For US$10 Million 36
Agenus Completes Private Placement Of Shares For US$8 Million 37
Agenus Completes Private Placement Of Shares For US$3 Million 38
Agenus Completes Public Offering Of Common Stock For US$7 Million 39
Antigenics Completes Private Placement Of Shares 41
Debt Offering 42
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 42
Agenus Completes Private Placement Of Notes Due 2015 For US$5 Million 43
Acquisition 44
Agenus Acquires PhosImmune 44
Agenus Completes Acquisition Of 4-Antibody For US$50 Million 45
Agenus Inc - Key Competitors 47
Key Employees 48
Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
May 04, 2017: Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update 50
Mar 09, 2017: Agenus Reports Fourth Quarter and Full Year 2016 Results 52
Oct 27, 2016: Agenus Reports Third Quarter Financial Results and Recent Highlights 54
Jul 28, 2016: Agenus Reports Second Quarter 2016 Financial Results and Operational Progress 55
Apr 28, 2016: Agenus Reports First Quarter 2016 Financial Results and Operational Progress 56
Mar 03, 2016: Agenus Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights 57
Corporate Communications 59
Mar 30, 2017: Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies 59
Jan 30, 2017: Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer 60
May 19, 2016: Agenus Appoints Ulf Wiinberg to Board of Directors 61
Product News 62
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN1884 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 62
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 63
Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-CTLA-4 Antibody 64
Clinical Trials 65
Apr 27, 2016: Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List Of Tables

Agenus Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Agenus Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Agenus Acquires Antibody Manufacturing Facilities from XOMA 12
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 13
Agenus Acquires Antibody Assets of Celexion 14
PhosImmune Raises Funds through Venture Financing 15
Agenus Enters into Agreement with National Cancer Institute 16
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 16
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 18
4-Antibody Enters Into Co-Development Agreement With Human Genome Sciences 18
4-Antibody Enters Into Co-Development Agreement With Ludwig Institute 19
Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center 20
Agenus Enters into Licensing Agreement with IONTAS 21
Incyte to Enter into Licensing Agreement with Agenus 21
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 23
Agenus Enters into Licensing Agreement with Diatheva 24
Merck Extends Licensing Agreement with Agenus 25
PhosImmune Enters into Licensing Agreement with Pure MHC 26
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 26
Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon 27
Agenus Enters Into Licensing And Development Agreement With NewVac For Oncophage 28
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon 29
Agenus Plans to Raise Funds through Public Offering of Shares 30
Agenus Raises USD80 Million in Public Offering of Shares 31
Celexion to Sell Shares of Agenus for USD4.3 Million 33
Agenus to Raise USD35 Million in Private Placement of Common Stock 34
Agenus Completes Public Offering Of Shares For US$60 Million 35
Agenus Completes Private Placement Of Shares For US$10 Million 36
Agenus Completes Private Placement Of Shares For US$8 Million 37
Agenus Completes Private Placement Of Shares For US$3 Million 38
Agenus Completes Public Offering Of Common Stock For US$7 Million 39
Antigenics Completes Private Placement Of Shares 41
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 42
Agenus Completes Private Placement Of Notes Due 2015 For US$5 Million 43
Agenus Acquires PhosImmune 44
Agenus Completes Acquisition Of 4-Antibody For US$50 Million 45
Agenus Inc, Key Competitors 47
Agenus Inc, Key Employees 48
Agenus Inc, Subsidiaries 49

List Of Figures

Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

RELATED REPORTS

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Agenus Inc (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review

Agenus Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review

FAQs